Answers are grounded in this paper and cite their sources.
Background/Objectives: Molecular nuclear imaging has substantially advanced the diagnosis and monitoring of neurodegenerative disorders over the past three decades, yet no previous evidence synthesis has mapped the full breadth of amyloid, tau, dopaminergic and emerging protein-specific tracer research against a single conceptual framework. This scoping review was undertaken to map the available evidence on molecular nuclear imaging in neurodegenerative disorders between 1 January 1992 and 31 March 2025, to identify the tracer classes studied, the clinical questions addressed, the source-type distribution of the literature, and the research gaps that would inform future systematic reviews or regulatory submissions. Methods: We followed the JBI methodology for scoping reviews and report against the PRISMA Extension for Scoping Reviews (PRISMA-ScR 2018). A Population–Concept–Context (PCC) framework was pre-specified. Population: adults with neurodegenerative disorders (Alzheimer’s disease and related dementias, Parkinson’s disease and related parkinsonisms, dementia with Lewy bodies, atypical tauopathies, multiple system atrophy, frontotemporal lobar degeneration). Concept: molecular nuclear imaging using amyloid, tau, dopaminergic, α-synuclein or TDP-43 tracers. Context: clinical or clinical-translational applications in humans. Searches were executed in PubMed/MEDLINE, Scopus and Web of Science and supplemented with grey literature. Consistent with scoping-review methodology, primary human clinical studies, systematic and narrative reviews, consensus statements, procedure standards and clinical guidelines were all eligible as sources of evidence. Sources were charted (not extracted) and synthesised through thematic mapping; a formal critical appraisal of individual sources was not conducted, consistent with JBI guidance. Results: Fifty-two sources of evidence were mapped; 43 primary human clinical studies and 9 consensus statements, procedure standards and clinical guidelines. The mapped evidence spans amyloid PET (first demonstrated with 11C-PiB in 2004, succeeded by three 18F-labelled agents with FDA/EMA approval), tau PET (first-generation 18F-flortaucipir with documented off-target binding, and second-generation 18F-MK-6240, 18F-PI-2620, 18F-RO-948, 18F-PM-PBB3 and 18F-GTP1), dopaminergic imaging (123I-ioflupane/FP-CIT SPECT, 18F-FDOPA and 18F-FE-PE2I PET), and emerging α-synuclein tracers in preclinical or early-phase human evaluation (18F-ACI-12589, 18F-F0502B, 11C-MODAG-005 and SPAL-T-06). Three thematic gaps dominate: (i) absence of head-to-head comparative studies between amyloid tracers and between tau tracers, (ii) under-representation of α-synuclein PET at the clinical-validation stage, with no tracer yet approved for routine use, and (iii) scarcity of standardised quantification thresholds for therapeutic monitoring in the anti-amyloid immunotherapy era. Conclusions: The mapped evidence base is methodologically mature for amyloid and tau PET and for dopaminergic imaging, but under-developed for α-synuclein and TDP-43 imaging and for threshold-based therapeutic monitoring. The research-gap matrix proposes four focused systematic-review questions as priorities for the next decade.
No takes yet. Share an insight, caveat, or question.
Alqahtani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: